Objectives

After participating in this educational activity, attendees should be able to:

1|Discuss various conceptual frameworks of combination therapy
2|Describe current evidence for advanced combination therapy in IBD
3|Outline the future of advanced combination therapy
4|Apply recommendations for current practice

Presenter(s): 

Marla Dubinsky, MD
Professor of Pediatric and Medicine
Chief Division Pediatric GI and Nutrition
Co-Director Susan and Leonard Feinstein IBD Center
Director, Marie and Barry Lipman IBD Preconception and Pregnancy Planning Clinic
Icahn School of Medicine Mount Sinai, New York
Co-Founder & CEO, Trellus Health

 

NameRoleFinancial Relationship DisclosuresDiscussion of
Unlabeled/Unapproved Uses of
Drugs/Devices in Presentation?

Marla Dubinsky, MD   

Speaker  

Consultant:  Abiva, Abbvie, Alimentiv, Amgen, AstraZeneca   
Bristol Myers Squibb, Celltrion, Eli Lilly,
Genentech, Janssen, Johnson & Johnson,
Merck & Co., Pfizer, Prometheus Laboratories,
Sanofi, Spyre, Takeda, Target RWE

Real world studies on dual therapy will be discussed and trials

Session date: 
02/11/2025 - 8:00am to 9:00am EST
Location: 
Chestnut 1 A/B
759 Chestnut Street
Springfield, MA 01199
United States
  • 1.00 ACPE Contact Hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC Contact Hours
  • 1.00 IPCE Credit Hour(s)

Please login or register to take this course.